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2Abstract
p21Waf1 (p21) was described as a cyclin-dependent kinase inhibitor, but other p21 
activities have subsequently been described, including its ability to inhibit apoptosis in 
some models. Comparative work on the human colon cancer isogenic cell lines HCT116 
and HCT116p21-/- led to the proposal that p21 protects colon cancer cells against 
apoptosis by genotoxic drugs. We asked whether p21 also protected from cell death 
induced by non-genotoxic drugs, such as tyrosine kinase inhibitors. We found that p21-
deficient cells were dramatically more sensitive towards imatinib and gefitinib than 
parental cells. Interestingly, HCT116p21-/- also showed higher basal activity of protein 
kinases as c-Abl, c-Src, and Akt. We generated HCT116p21-/- sublines with inducible
p21 expression and found that p21 did not rescue the hypersensitivity to imatinib. 
Moreover, down-regulation of p21 by enforced c-Myc expression or by p21 siRNA did 
not sensitize parental HCT116 cells. We found that, in HCT116p21-/- cells, p53 showed 
higher stability, higher transcriptional activity and phosphorylation in serines associated 
with p53 activity. Furthermore, silencing of p53 with siRNA and inactivation of p53 
with a dominant negative mutant rescued the hypersensitive response to kinases 
inhibitors, 5-fluorouracil and adriamycin in HCT116p21-/- cells. Consistently, 
HCT116p53-/- cells are more resistant to imatinib than parental cells, suggesting that 
imatinib activity is partly dependent on p53 in colon cancer cells. We conclude that high 
p53 activity, rather than p21 deficiency, is the mechanism responsible for
hypersensitivity to drugs of HCT116p21-/- cells. Therefore the role of p21 on apoptosis 
of HCT116 colon cancer cells should be re-evaluated.
1. Introduction
p21Waf1 (p21 herein after) is a member of the Cip/Kip family inhibitors of cell 
cycle progression. The first discovered and best studied biochemical activity of p21 is to 
inhibit Cdks, consistent with its activity as cell cycle inhibitor [1-4].  However, more 
recent studies have shown that p21 has additional functions as differentiation inducer 
[5] and as an inhibitor of apoptosis induced by DNA-damaging agents [6-8]. Since 
cancer cells can escape death induced by chemotherapeutic drugs, this latter p21 activity 
is of pivotal importance in human cancer therapy.
3p21 is a p53 target gene and is a relevant mediator of p53-cell cycle arrest [9-
11]. A role of p21 in cancer has been demonstrated in vivo, as p21-null mice develop 
tumours spontaneously  [12] and show increased tumour susceptibility using chemical 
carcinogenesis [13-16]. Although there are examples of p21 acting as an apoptosis 
inducer [17-20], the results in most models suggest it has an apoptosis protective effect. 
One of these cell models consists of the human colon cancer cell line HCT116 and its 
isogenic derivative HCT116p21-/-, generated by disruption of both p21 alleles through 
homologous recombination [21]. Work with these cell lines suggested that p21 
protected from apoptosis induced by adriamycin (doxorubicin) [22]. Later on, many 
reports have argued for a protective role of p21 against apoptosis induced by DNA-
damaging agents and other stimuli as hypoxia using the HCT116 model system (a non-
exhaustive list is shown in Supplemental Table 1).  
In this work we asked whether p21 also played a role in the cell death induced 
by non-genotoxic drugs in the HCT116 model. We chose imatinib as the main drug for 
our studies because it is tyrosine kinase inhibitor (with higher activity against c-Abl, 
Bcr-Abl and c-Kit) widely used in human cancer therapy [23,24]. We found that the 
cytotoxic effect of imatinib, gefitinib and adriamycin was much higher on the p21-
deficient HCT116 cells than on parental cells, but, surprisingly, this hypersensitivity 
was due to p53 overexpression and independent from p21.
2. Material and Methods
2.1 Cell lines, transfections and mice
Colon cancer cell line HCT116 and its isogenic derivatives HCT116p21-/- [21]
and HCT116p53-/- cells [22] were grown in RPMI 1640 (Invitrogen) with 8% fetal calf 
serum and gentamycin (80 g/ml).  HKO-MTp21 cell line was generated cotransfecting 
HCT116p21-/- cells with the pM6-p21 construct (carrying a Zn2+-inducible p21) [25]
and the pLPCX vector in a proportion 6:1. Transfections were carried out with 
Lipofectamine (Invitrogen) and transfectants were selected with 0.25 μg/ml of 
puromycin (Sigma). HKO-MTp21 cells were incubated with 75 M ZnSO4 to induce 
p21. For silencing of p21, HCT116 cells and derived cell lines were transduced with 
empty vector (pRetroSuper), and vector carrying two different short-hairpin constructs 
for human p21 (shp21B and C). The targeted sequences were 
AACACCTCCTCATGTACAT (shp21B) and GCGACTGTGATGCGCTAAT 
4(shp21C). Overexpression of p21 was achieved by adenoviral infection. HCT116p21-/-
cells were infected with adenovirus carrying p21 gene and GFP [26] and 24 h after 
infection whole-cell protein extracts were analysed by immunoblot. GFP-expressing 
cells were above 80% in all adenoviral infections. For silencing of p53, HCT116p21-/-
cells were transduced with pSuperRetro-shp53 virus [27] and a polyclonal transduced 
cell line, Hp21KO-shp53, was selected with 0.5 μg/ml of puromycin.  Hp21KO-pSR are 
HCT116p21-/- cells transduced with the empty vector.  HCT116p21-/- cells were 
transfected with an expression vector for pcDNA3-DDp53 [28] and, to allow selection, 
a vector carrying a puromycin resistance markers (pLPCX) in a proportion 6:1 
(DDp53:pLPCX). Transfections were carried out with Lipofectamine and transfectants 
were selected with 0.5 μg/ml of puromycin. A pool of five transfectants was selected 
and the presence of the DDp53 isoform analysed by immunoblot. p21-deficient mice 
(B6;129S2-Cdkn1atm1Tyj/J) [9]were obtained form Jackson Laboratories.
2.2 Proliferation, annexin V binding and cell cycle assays
Proliferation assays were performed to compare the response of cells to drugs. 
80,000 cells (for HCT116p21-/-) or 50,000 cells (for the other cell lines) were plated on 
12-multiwell plates and 24 h after plating, increased concentrations of imatinib 
(provided by Novartis), gefitinib (provided by Astra-Zeneca), adriamycin (Sigma 
Chemical Co.), 5-fluorouracil (5-FU) (Sigma Chemical Co.) or SU6656-001 (Biaffin)
were added. After 48 h cells were stained with crystal violet (1% in methanol), scanned 
and subjected to densitometric analysis. Clonogenic assays were performed plating 
5,000 cells on 6-multiwell plates and after one week colonies where stained as above 
and counted. For cell cycle analysis the cells were fixed in 90% ethanol at 4ºC, washed 
with PBS and incubated at 37ºC for 30 min with RNase (200 µg/ml) and 10 µg/ml 
propidium iodide (PI) (Sigma). The stained cells were analyzed by flow citometry on a 
FACScan flow cytometer (BD Bioscences) using the CellQuest software. Apoptosis 
was assessed by annexin V binding. Cells were treated with different imatinib 
concentrations for 48 h and annexin V binding was determined by flow cytometry and 
annexin V-phycoerythrin (BD Pharmingen).
2.3 Immunofluorescence staining, immunoblotting and protein kinase assays
Cells were fixed with paraformaldehyde and the presence of phosphorylated 
H2AX histone (γ-H2AX, monoclonal antibody from Upstate, ref. 05-636) or p21 
5(policlonal antibody C-19 form Santa Cruz Biotech.) were detected by 
immunofluorescence, using a FITC-conjugated secondary antibody (Dako, F0205). 
Samples were mounted with Vectashield (Vector) containing 4'-6-diamidino-2-
phenylindole (DAPI) to stain nuclei and examined under a fluorescence microscope 
(Zeiss-Axioskop2). Immunoblots were performed as previously described [25]. Blots 
were revealed with the ECL system (GE Healthcare). Antibodies used were: anti-
poy(ADP-ribose)polymerase (PARP) (H-250), anti-phospho-tyrosine (PY20), anti-actin 
(I-19), anti-p53 (FL-393), anti-Akt1/2 (H136), anti-c-Src (SRC2), anti-Erk2 (C14), anti-
phospho-Erk1/2 (E-4), anti-CDK2 (M2) from Santa Cruz Biotech; anti-p53 
phosphorylated in serines 6, 9, 15, 20, 37, 46 and 392 (ref. 9919) and anti-phospho Akt 
(ref. 9271) from Cell Signalling; anti-phospho-c-Src (44-660G) from BioSource; anti-c-
Abl (ref. 554104) from BD Pharmingen; anti-p21 (P-184) from Sigma, and anti-α-
tubulin antibody provided by Nicholas Cowan (New York University, New York). To 
assay CDK2 activity, protein extracts (1 mg per assay) were immunoprecipitated with 
1.5 µg of CDK2 antibody (same as above) and collected on Gammabind sepharose 
beads (Pharmacia). Kinase activity was measured on histone H1 (Roche Biochemicals) 
as a substrate as described [25]. An aliquot of the immunoprecipitate was analysed by 
immunoblot for p21 and CDK2 expression.
2.4 Reporter-luciferase assays
p53 transcriptional activity of HCT116 and HCT116p21-/- was measured with 
three promoter-luciferase constructs: PG13-Luc, p21-Luc and MDM2-Luc, as well as 
the promoterless pGL2-basic vector (Promega)  used as negative control. One million of 
cells were transfected with Lipofectamine and 1 μg of the luciferase constructs plus 0.1 
μg of pRL-null for transfection normalization. After 36 h cells were lysed and luciferase 
activity was assayed with the Dual Luciferase kit from Promega as instructed by the 
manufacturer. Luciferase activity was normalized to the Renilla internal control. Each 
point corresponds to the mean of two different experiments done in duplicate. 
Activation is relative to the values obtained with HCT116 cells transfected with the 
corresponding reporter.
2.5 Gene expression analysis
HCT116 and HCT116p21-/- cells were untreated or treated with 15 µM imatinib 
for 48 h. Total RNA was extracted (RNeasy kit, Qiagen), labelled and hybridized to a 
6membrane macroarray containing probes for 96 apoptosis-related genes (Human 
Apoptosis Gene Array”, SuperArray Bioscience Corporation), following the 
manufacturer indications. The membrane was washed and the radioactivity measured in 
a Molecular Imager apparatus (BioRad). For each gene the signal was normalized to the 
control genes in the array, and the ratio between the mRNA levels in control cells and 
cells treated with imatinib was calculated.
3. Results
3.1 HCT116p21-/- cells are more sensitive to kinase inhibitors
In view of the high sensitivity of HCT116p21-/- to genotoxic drugs, we took 
advantage of this model to determine whether p21 played a role in the response to drugs 
that do not directly induce DNA damage such as tyrosine-kinase inhibitors in HCT116 
and HCT116p21-/-. We tested imatinib (which shows higher activity against Bcr-Abl, c-
Abl and c-Kit) and gefitinib (with highest specificity against epidermal growth factor 
receptor). The results demonstrated that p21-deficient cells were dramatically more 
sensitive against imatinib and gefitinib than parental cells. We also tested p53-deficient 
cells [29] and found that these cells were more resistant to the kinase inhibitors that the 
p21-deficient cells (Fig. 1a). As a parallel approach we performed clonogenic assays, 
which also demonstrated the hypersensitivity of HCT116p21-/- cells to protein kinase 
inhibitors [30] (Fig. 1b). As positive controls for cell death we used adriamycin and 5-
FU and we confirmed the reported hypersensitivity to both drugs of p21-deficient cells 
[22,31-33] (Fig. 1a, b).
A time-course proliferation assay in response to imatinib confirmed that 
HCT116p21-/- cells were more sensitive than the parental cells. The imatinib effect on 
p21 deficient cells was cytotoxic as growth did not resume upon removal of the drug 
(Fig. 1c). The results also showed that, in the absence of drugs, HCT116p21-/- cells 
grow ~five-fold slower than parental cells. The cytotoxic effect of imatinib on p21-
deficient cells is mediated by apoptosis as demonstrated by proteolytic cleavage of 
PARP assayed by immunoblot (Fig. 1d), by annexin V binding assayed by flow 
cytometry (Fig. 1e) and by accumulation of sub G0/G1 cells (not shown). The effect of 
imatinib was partly dependent on p53, as p53-deficient cells were more resistant to high 
imatinib concentrations (20-60 μM) than parental cells, as shown by cell growth assays 
(Fig. 1f) and annexin V binding (Fig. 1g). 
7It was surprising that p21 deficiency resulted in such high sensitivity to the 
tyrosine kinase inhibitors, as well as its partial dependence on p53, in a similar way than 
genotoxic drugs as adriamycin or 5-FU. Therefore, we tested the possibility that 
imatinib indirectly induces DNA damage in HCT116 cells by assaying the accumulation 
in the cell nuclei of foci with phosphorylated histone H2AX (γ-H2AX, a marker of 
genomic damage). The results (Fig. 2a) showed that imatinib did not induce nuclear γ-
H2AX foci, contrary to cells treated with adriamycin, which were used as positive 
control. However, imatinib reached its intracellular targets in HCT116, as 
autophosphorylation of c-Abl kinase was severely inhibited upon treatment with 
imatinib (Fig. 2b). Interestingly, basal c-Abl expression and activity were significantly 
higher in HCT116p21-/- than in parental cells.  We did not detect expression of other 
imatinib targets as c-Kit and EGF receptor in HCT116 (not shown). It was striking the 
higher level of c-Abl activation observed in HCT116p21-/- cells, and we asked whether 
other kinases besides c-Abl were hyperactivated in HCT116p21-/- cells. Using phospho-
specific antibodies we found an enhanced phosphorylation of Akt, Erk and c-Src 
kinases in HCT116p21-/- cells as compared to parental cells (Fig. 2c). Imatinib also 
resulted in the inactivation of the c-Src kinase (Fig. 2d), consistent with the described 
requirement of c-Abl for c-Src activity [34].
3.2 p21 deficiency is not responsible for the hypersensitive phenotype of HCT116p21-/-
cells
To directly test whether p21 deficiency is responsible for the hypersensitive 
phenotype of p21-deficient cells, we generated cell lines with inducible expression of 
p21. Cells were transfected with an expression vector where the human p21 cDNA is 
under control of the metallothionein promoter and its expression is induced by Zn2+ in 
the culture media [25]. The kinetics of p21 induction in one selected transfectants
(Hp21KO-MTp21) is shown in Fig. 3a. Most of exogenous p21 remains in the cell 
nuclei, as assessed by immunofluorescence (Fig. 3b). We tested the functionality of the 
ectopic p21 by assaying the kinase activity of CDK2 upon induction of p21 with Zn2+. 
The results showed that induction of p21 in Hp21KO-MTp21 resulted in effective 
inhibition of CDK2 (Fig. 3c). Consistently, induction of p21 reduced the fraction of 
cells in G1 phase of the cell cycle, as assayed by flow cytometry of PI-stained cells 
(Fig. 3d), as cells in G1 transverse into G2/M but cannot begin a new S phase. This is 
consistent with the reported effect of p21 as an inductor of G2 accumulation [35,36].
8Having characterized the Hp21KO-MTp21 cell line, we next asked whether 
restoring p21 expression in HCT116p21-/- cells conferred resistance to imatinib. 
Surprisingly, the induction of p21 did not alter the sensitivity of the cells towards 
imatinib, as determined by cell growth (Fig. 3e) and the fraction of apoptotic cells as 
determined by annexin V binding (Fig. 3f). In addition, induction of p21 in Hp21KO-
MTp21 cells did not modify the sensitivity to adriamycin (not shown). 
The above results from p21 overexpression suggested that p21 deficiency was 
not responsible for the enhanced cytotoxic response to drugs. We sought to confirm this 
by the opposite approach, i.e., decreasing p21 expression in wild-type HCT116 cells 
through RNA interference. We generated a polyclonal cell line expressing a p21 short-
hairpin vector by retroviral transduction. These cells, termed HCT-shp21B, showed 
reduced levels of p21 protein levels with respect to parental cell line (Fig. 3g). 
Adriamycin potently up-regulated p21, as previously reported [21,37] and we found that 
HCT-shp21B showed reduced p21 in the presence of adriamycin, as compared to 
control cells (Fig. 3g). In contrast, imatinib did not modify p21 levels and the cells also 
showed reduced p21 levels upon treatment with imatinib, with respect to parental cells
(Fig 3g). Thus, we next asked whether p21 suppression modified the cytotoxicity
mediated by drugs. We found that the response to adriamycin, 5-fluorouracil, imatinib 
and gefitinib was similar for HCT116 and HCT-shp21B cell lines (Fig. 3h). Also, HCT-
shp21B and parental HCT116 show similar sensitivity to high imatinib concentrations 
(20-60 μM) (not shown). These results suggest that p21 deficiency is not responsible for 
the sensitivity to imatinib. In a complementary approach to decrease endogenous p21 
we generated cell lines transfected with an conditional Myc, a transcription factor 
known to repress p21 expression in many cell lines including HCT116 [38,39].We 
generated HCT116 cells expressing c-MycER, a Myc fusion protein which is activated 
by 4-hydroxytamoxifen. Addition of 4-hydroxytamoxifen to these cells resulted in p21 
down-regulation (Supplemental Fig 1). However, c-Myc activation did not result in a 
significant change in sensitivity to imatinib or adriamycin, as determined by 
proliferation assays, annexin V binding and PARP proteolysis (Supplemental Fig. 1). 
Altogether, the results indicate that p21 deficiency is not responsible for the 
hypersensitive response of HCT116p21-/- cells to drugs as tyrosine kinase inhibitors or 
DNA-damaging drugs.
93.3 p53 is stabilized and hyperactivated in HCT116p21-/- cells 
In an attempt to explain the higher sensitivity of HCT116p21-/- cells to drugs we 
analysed the expression of genes related to apoptosis through macroarray hybridization. 
We found that the mRNA expression of several p53 target genes (e.g., GADD45, DR5, 
CD95, BAX, CHEK1, TRAF1) was up-regulated in response to imatinib in the p21-
deficient cells as compared to parental cells (Fig. 4a). This finding suggested that p53 
might be involved in the hypersensitive phenotype of HCT116p21-/- . Thus, we studied 
the status of p53 in HCT116p21-/- and found that p53 protein levels were dramatically 
elevated with respect to parental cells (Fig. 4b), as already observed [40-43]. Most of 
the p53 mutations found in cancer render a more stable protein, and it was conceivably 
that mutation in p53 was selected during the multiple passages of the cell line. 
However, we did not find mutations in exons 2-11 of the p53 gene of the HCT116p21-/-
cell line used in our studies (not shown). In contrast we found that in HCT116p21-/-
cells but not in the parental cells, p53 was hyperphosphorylated in residues known to be 
important for p53 stabilization and/or transactivation: Ser-9, Ser-15 and Ser-392 (Fig.
4b). We did not detect significant changes in the phosphorylation of other residues 
tested (Ser-6, Ser-20, Ser-37, Ser-46) (not shown). It was expected that these 
modifications would result in increased p53 stability. To determine p53 stability, 
HCT116 and HCT116p21-/- cells were treated for the indicated periods of time with 50 
μg/ml of the protein synthesis inhibitor cycloheximide and the p53 levels were assessed 
by immunoblot. The results demonstrated that p53 had higher stability in HCT116p21-/-
(Fig. 4c). Moreover, reporter-luciferase assays with three different p53-responsive 
promoters revealed an increased transcriptional activity of p53 in HCT116p21-/- cells 
(Fig. 4d). Therefore, HCT116p21-/- expressed higher levels of active p53 than the 
parental cell line.
We next asked whether the elevated p53 levels in HCT116p21-/- cells depended 
on p21 deficiency. The results (Fig. 5a) revealed that induction of p21 in Hp21KO-
MTp21 did not modify p53 levels and p53 phosphorylation. Also, reduction of p21 
levels in HCT116 cells (i.e., in HCT-shp21B cells) did not result in increased total p53 
levels or phospho-Ser15-p53 levels (Fig. 5b). Moreover, high transient p21 levels 
achieved by adenoviral infection in HCT116p21-/- cells did not result in any decrease of 
p53 levels (Fig. 5c). Cells acutely infected with p21 adenovirus did not show any 
increase in resistance towards imatinib or adriamycin after 24 h of treatment with 
respect to cells infected with a control virus, assessed by sub G0/G1 fraction and 
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annexin V binding (not shown). At longer infection times (36-48h) the p21 virus 
induced cell death (Fig. 5d). Finally, we could not detect differences in p53 protein 
levels (as assayed by immunoblot) in ascendant colon from p21-deficient mice [9] and 
parental mice (not shown). In summary, the results indicate that HCT116p21-/- cells 
express higher p53 levels and exert higher p53 activity than parental cells, and that this 
was independent from its p21 deficiency.
3.4 High p53 levels are responsible for the hypersensitive phenotype in HCT116p21-/-
cells  
We finally asked whether the increased sensitivity of HCT116p21-/- to drugs was 
a consequence of the p53 overexpression in HCT116p21-/- cells. To test this hypothesis 
we generated HCT116p21-/- sublines with reduced p53 expression and tested their 
response to imatinib and adriamycin. Cells were transduced with retrovirus expressing a 
short-hairpin p53 [27]. The transduced cells (Hp21KO-shp53) expressed reduced p53 
levels (Fig. 6a). We also generated transfectant HCT116p21-/- cell lines expressing a 
p53 fragment (DDp53) that acts as a dominant negative p53 mutant [28]. We chose a 
cell line termed Hp21KO-DDp53 and the expression of DDp53 was confirmed by 
immunoblot (Fig. 6b). Cell proliferation assays demonstrated that the cell line with 
reduced p53 (Hp21KO-shp53) grew faster than the parental HCT116p21-/-, and at a 
similar rate than the wild-type HCT116 cells (Fig 6c).
We next asked whether p53 inactivation in these cells conferred higher 
resistance to kinase inhibitors. As shown in growth curves of Fig. 7a, silencing of p53 
completely rescued the growth inhibition by low imatinib and gefitinib doses, as 
p21KO-shp53 grew at the same rate than parental HCT116 cells. Confirming our 
previous results (Fig. 3), the reduction of p21 (i.e., HCT-shp21B cells) did not confer 
higher sensibility in this assay. The inactivation of p53 with the DDp53 mutant 
(Hp21KO-DDp53 cells) also reversed the hypersensitive phenotype of HCT116-/- cells
to a similar extent than in Hp21KO-shp53 cells (Fig 7b). Moreover, reduction of p53 
levels or p53 activity resulted in increased resistance to the apoptosis induced by 
imatinib, as assessed by annexin V binding assay (Fig. 7c). Proliferation assays also 
confirmed that impairment of p53 function reverted the hypersensitive phenotype of 
HCT116p21-/- cells towards adriamycin, imatinib and gefitinib (Fig. 7d). These results
are consistent with the increased resistance to high imatinib concentrations of p53-
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deficient HCT116, described above (Fig. 1). Thus, reduction of p53 levels or activity
rescued the slow-growing and the hypersensitive phenotypes of HCT116p21-/-. We 
showed above (Fig. 2) that despite the hypersenstivity to imatinib, HCT116p21-/- cells 
had higher c-Abl and c-Src protein kinases activity. Thus we asked whether impairment 
of p53 function would also antagonize these activities. The results demonstrate that c-
Abl and c-Src activities are decreased in Hp21KO-shp53 and Hp21KO-DDp53 with 
respect to parental HCT116p21-/- cells (Fig. 7e). Taken together, our results strongly 
suggest that p53 is responsible for the hypersensitivity to tyrosine kinases inhibitors in
this model.
12
4. Discussion
We demonstrate here that HCT116p21-/- cells are dramatically more sensitive to 
imatinib and gefitinib than parental cells. Both inhibitors are now widely used in 
therapy of human cancer. Our results extend to tyrosine kinase inhibitors the previous 
observation with DNA-damaging drugs as adriamycin or 5-FU, which are also more 
cytotoxic to HCT116p21-/- cells [22,31-33]. However, restoring p21 expression in the 
p21-deficient cells did not modify the hypersensitive response to imatinib and 
adriamycin, and silencing p21 in parental cells did not confer higher sensitivity to the 
drugs. Surprisingly, this hypersensitivity is not due to p21 deficiency but to p53
overexpression in HCT116p21-/- cells, as the silencing or inactivation of p53 confers a 
lower sensitivity towards these drugs, and similar to that of parental cells. 
It is noteworthy and previously unnoticed that p53 also confers sensitivity to 
gefitinib and imatinib, although ten-fold higher imatinib concentrations are required to 
achieve a cytotoxic effect in this colon cancer cells than in chronic myeloid leukemia 
cells (the major clinical application of imatinib). Conversely to HCT116, chronic 
myeloid leukemia cells express Bcr-Abl kinase as imatinib target. The dependence on 
p53 for imatinib response in HCT116, which do not express Bcr-Abl but express c-Abl, 
extends previous findings in chronic myeloid leukemia where p53 inactivation is 
associated to imatinib resistance [44,45].
p53 overexpression in HCT116p21-/- was due to enhanced stability of the p53 
protein. The reason for this effect in HCT116p21-/- cells is unclear, but it is not 
dependent on p14ARF and Mdm2 expression [42,46] and our unpublished results]. We 
have shown that HCT116p21-/- cells express high levels of activated c-Abl kinase (Fig.
2b), and it is established that c-Abl stabilizes p53 by inhibiting Mdm2-mediated 
degradation of p53 [reviewed in [47]. So, high c-Abl expression could explain the 
stability and elevated p53 levels in HCT116p21-/- cells.  It is also noteworthy the high 
levels of activated kinases (e.g. c-Abl, Akt, c-Src and Erk2) in p21-deficient cells. This 
is striking as some of these kinases have been associated to cell survival in different 
systems. We hypothesize that the HCT116p21-/- cell line, besides its deficiency in p21, 
acquired additional genetic or epigenetic changes during the selection process leading to 
high basal kinase activity which would stabilize p53 through different pathways. This 
would result in cells showing  a slower growth rate and higher sensitivity to drugs.
Regardless of the mechanism that led to the high-p53 and hypersensitive 
phenotype of HCT116p21-/- cells, our results invite to reconsider many of the reported 
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conclusions on the anti-apoptotic effect of p21 in colon cancer cells. An antiapoptotic 
role for p21 has been demonstrated in several cell culture models from different tissues
[reviewed in [7,8,48], and can explain the decreased rate of radiation-induced 
tumorigenesis p21-deficient mice [12,49]. In the HCT116 model, comparative work 
with HCT116 and HCT116p21-/- cell lines has generated multiple reports arguing that 
p21 loss sensitizes these cells for apoptosis induced by a number of antitumoral drugs 
(Supplemental Table 1). Although it is unknown whether our results can be extended to
all drugs, the work described here challenge these conclusions as we demonstrate that 
the hypersensitive phenotype for the drugs tested in our work, depends on the high p53 
levels in the HCT116p21-/- cell line and not on the p21 deficiency.
In support of this hypothesis, a recent report indicates that the hypersensitivity to 
chromium-induced DNA damage in HCT116p21-/- is also mediated by p53 [50]. In vivo
inactivation of p21 in mice resulted in a significant increase in the frequency and size of 
intestinal tumors in two different models of colon carcinogenesis [51,52]. These results 
are not consistent with the idea that p21 deficiency confers an apoptosis-prone and 
slow-growth phenotype whereas they are in agreement with our results in the HCT116 
model. Moreover, trials in human colorectal cancer with different drugs have failed to 
demonstrate a favorable prognostic role for elevated p21 expression in overall survival 
[reviewed in [53]. This observation is at odds with an anti-apoptotic function of p21 in 
human colon cancer cells. We conclude that p21 does not have a protective effect on 
drug-induced cell death in the HCT116 model and that the role of p21 in colon cancer 
cell apoptosis should be re-evaluated.
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Figure legends
Fig. 1. HCT116p21-/- cells are hyper-sensitive to the cytotoxic effects of imatinib. (a) Cells of 
the indicated cell lines were treated with the indicated concentrations of imatinib, gefitnib, 
adriamycin and 5-FU. Cell proliferation was determined after 48 h and expressed as a 
percentage of the proliferation of untreated cells. (b) Clonogenic assay of the indicated cell lines 
treated with imatinib, gefitinib and 5-FU for 5 days after crystal violet staining. (c) Growth 
curves of the indicated cell lines in the presence of imatinib. “W” indicates the time point at 
which the cells were washed to remove imatinib. Note that the scales for both cell lines are 
different.  Dotted line in the left graph corresponds to untreated HCT116p21-/- for comparison 
with wild-type HCT116. (d) Apoptosis assessed by the proteolytic cleavage of PARP.  HCT116 
and HCT116p21-/- cells were treated with the indicated concentrations of imatinib and 0.5 μM 
adriamycin (ADR) for 48 h. Whole cell protein extracts were analysed by immunoblot with 
antibodies anti-PARP and anti- α-tubulin as a loading control. (e) Apoptosis induction by 
imatinib as assessed by annexin V binding. Cells were treated with different imatinib 
concentrations for 48 h. Annexin V binding was determined by flow cytometry. (f) Cell 
proliferation of HCT116 and HCT116p53-/- cells treated with high imatinib concentrations for 
48 h. Data are means from three experiments ± S.E.M. (g) Apoptosis induction by imatinib as 
assessed by annexin V binding in cells treated with high imatinib concentrations for 48 h. Data 
are means from two experiments ± S.E.M. 
Fig. 2. Imatinib targets in HCT116p21-/-. (a) Imatinib does not induce H2AX phosphorylation. 
Cells were treated with imatinib and (as a positive control) with 0.5 μM adriamycin for 48 h and 
fixed with paraformaldehyde. The presence of phosphorylated H2AX histone (γ-H2AX) was
detected by immunofluorescence. The cells were counterstained with DAPI to stain nuclei and 
the fraction of positive cells is indicated in each case. Representative images are shown.  (b) c-
Abl inactivation by imatinib in HCT116 and HCT116p21-/- cells. Cells were incubated for 48 h 
with imatinib and c-Abl was determined by immunoblot. To determine the phosphorylation of 
c-Abl the blot was probed with an anti-phospho-tyrosine antibody. Actin levels were also 
determined to assess protein loading. (c) Protein kinase activation in HCT116p21-/-. Cells were 
lysed and the levels of kinases indicated at the right were determined by immunoblot. Arrow 
marks the Erk2 band. Actin levels were also determined as a loading control. (d) c-Src 
inactivation by imatinib in HCT116 and HCT116p21-/- cells. Cells were incubated for 48 h with 
imatinib and phospho-c-Src and c-Src were determined by immunoblot.
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Fig. 3. Ectopic expression of p21 does not rescue the hypersensitive phenotype of HCT116p21-/-
.(a) Induction of p21 in Hp21KO-MTp21cells.  Cells were incubated with 75 μM ZnSO4 for the 
indicated periods of time and protein extracts were analysed by immunoblot with anti-p21 and 
anti-α-tubulin antibodies. (b) Induction and nuclear localization of p21 in Hp21KO-MTp21 
cells. Immunofluorescence analysis with anti-p21 antibody was performed in cells treated for 12 
h with 50 μM ZnSO4. Cells were counterstained with DAPI to stain nuclei. (c) Induction of p21 
in Hp21KO-MTcells inhibits activity kinase of CDK2. Cells were incubated with 75µM ZnSO4
during 24 hours. Lysates were immunoprecipitated with anti-CDK2 antibodies and assayed for 
kinase activity using histone H1 as substrate. Levels of CDK2 and p21 in the 
immunoprecipitates were determined by immunoblot. (d) Cell cycle analysis of HCT116, 
HCT116p21-/- and Hp21KO-MTp21 cells treated with 75 µM ZnSO4 for 4 days and assayed for 
the PI incorporation by flow cytometry. (e) Micrographs of HKO-MTp21 cells treated with 20 
μM imatinib for 48 h in the presence and absence of 75 μM ZnSO4 showing similar sensitivity 
in the presence and absence of the p21 inducer. (f) Apoptosis induction by imatinib as assessed 
by Annexin V binding. Cells of the indicated cell lines were treated with 20 μM imatinib for 24 
h. Annexin V binding was determined as in Figure 1. (g) Silencing of p21. Lysates were 
prepared from parental HCT116 and derived cell lines expressing two different short-hairpin 
constructs for human p21, one competent for silencing (HCT-shp21B) and another used as a 
negative control (HCT-shp21C), as well as cells transduced with empty vector (HCT-pRS). 
Cells were treated for 16 h with adriamycin (upper panel) and with imatinib (lower panel) to 
show p21 levels in the presence of the drugs. p21, α-tubulin and actin were detected by 
immunoblot. A short exposure of the film is also shown to demonstrate p21 downregulation in 
the presence of adriamycin. HCT116p53-/- cells was used as negative control of p53 expression 
in the lower-panel. (h) Proliferation assay of the indicated cell lines incubated with increased 
concentrations of adriamycin, 5-fluorouracil, gefitinib and imatinib. The cells were stained with 
crystal violet after 48 h of treatment. The numbers in the wells represent densitometric units
normalized to the value of untreated cells.
Fig. 4. p53 is stabilized and hyperactivated in HCT116p21-/- cells. (a) Induction of p53-target 
genes in HCT116p21-/- treated with imatinib. HCT116p21-/- and HCT116 were treated with 15 
μM imatinib for 48 h. The RNA was prepared and labelled and the expression of p53 target 
genes was determined by macroarray hybridization as described in Material and Methods. Data 
are normalized to the expression of each gene in parental HCT116 cells. (b) Levels of 
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phosphorylated p53 in HCT116 and HCT116p21-/- cells treated with imatinib for 48 h. Cells 
were lysed and the immunoblot were prepared using phospho-specific antibodies. As a control, 
a lysate from HCT116 cells treated with 0.5 μM adriamycin for 48 h (HCT+Adr) was included. 
(c) Immunoblot of HCT116 and HCT116p21-/- cells treated for the indicated periods of time 
with 50 μg/ml of cycloheximide (Chx). The blot was probed with anti-p53 and anti-actin 
antibodies. (d) p53 transcriptional activity of HCT116 and HCT116p21-/- measured with the 
three indicated luciferase constructs carrying p53-responsive elements. Data are means of two 
different experiments done in duplicate and are normalized to the values in HCT116 cells. Error 
bars represent S.E.M.
Fig. 5. Induction or repression of p21 does not modify p53 expression in HCT116 cells. (a)  
Induction of p21 does not modify p53 expression in HCT116. Whole-cell lysates from 
Hp21KO-MTp21 cells grown in the absence or presence of 50 μM ZnSO4 for 24 h (to induce 
p21) were analysed by immunoblot with antibodies against p53, p21, actin and Ser-15- and Ser-
392-phosphorylated p53. (b)  Silencing of p21 does not modify p53 expression in HCT116 
cells. Lysates of HCT1-shp21B (where p21 is silenced, Figure 3d), HCT-shp21C (expressing a 
control siRNA) and HCT-pRS (transduced with the empty virus) were analysed by immunoblot 
with the antibodies anti-p21, anti-total p53 and anti-phospho-serine-15-p53. The filter was 
stained with Ponceau Red to assess protein loading (c) Overexpression of p21 by adenoviral 
infection does not modify p53 expression in HCT116p21-/- cells. Cells were infected with 
adenovirus carrying p21 gene and GFP [26] and 24 h after infection whole-cell protein extracts 
were analysed by immunoblot with antibodies against p21, p53 and α-tubulin. (d) 
Overexpression of p21 did not confer protection to infected cells. HCT116p21-/- were infected 
with adenovirus p21 and GFP and 6h after infection cells were treated with 20 μM imatinib and 
1 μM adriamycin and micrographs were taken after 30 h of treatment.
Fig. 6. Impairment of p53 activity in HCT116p21-/- cells rescues the slow-growing phenotype.
(a) Silencing of p53 in Hp21KO-shp53 cells. Cell lysates from the indicated cell lines were 
analysed by immunoblot with anti-p53. The filter was stained with Ponceau Red to assess 
protein loading. (b) Expression of DDp53. Cell lysates from the indicated cell lines were 
analysed by immunoblot with anti-p53 antibody. The filter was stained with Ponceau Red to 
assess protein loading (c) Cell proliferation of HCT116, HCT116p21-/- and Hp21KO-shp53 
cells. Cells were plated at equivalent densities in parallel dishes and tripsinized and counted 
during four days. Data are mean from two experiments ± S.E.M.
22
Fig. 7. Hypersensitivity to imatinib of HCT116p21-/- cells depends on high p53 levels and 
activity. (a) Growth curves of the indicated cell lines in the presence of imatinib and gefitinib. 
Cells were plated at equivalent densities and tripsinized and counted during five days. (b) 
Micrographs of the indicated cell lines treated with 20 μM imatinib for 48 h showing the 
reduced sensitivity to imatinib of Hp21KO-shp53 and Hp21KO-DDp53. (c) Cells were treated 
for 48 h with imatinib and the fraction of cells binding annexin V was determined as in Figure 
1. (d) Proliferation assay of the indicated cell lines incubated with increased concentrations of 
adriamycin, imatinib and gefitinib. The cells were stained with crystal violet after 48 h of 
treatment. The numbers in the wells represent densitometric units normalized to the growth of 
untreated cells. (e) Silencing of p53 protein in HCT116p21-/- downregulated the activity of c-Src 
and c-Abl. Whole-cell lysates from HCT116, HCT116p53-/-, HCT116p21-/-, Hp21KO-shp53, 
Hp21KO-DDp53 were analysed by immunoblot with antibodies against p53, p-c-Src, c-Src, p-
Abl, c-Abl and actin.
Figure 1 Ferrándiz et al.
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COVER LETER
Dear DNA Repair Editor
We thank you very much for the review of our manuscript (MS) entitled 
“HCT116 cells deficient in p21Waf1 are hypersensitive to tyrosine kinase inhibitors and 
adriamycin through a mechanism unrelated to p21 and dependent on p53” by Ferrandiz 
et al.
The comments of the reviewers have certainly improved the MS. After 
performing a series of new experiments we believe that we have appropriately 
responded to all the points raised by the two reviewers. To illustrate of our responds we 
include in our response letter four “Figures for Reviewers”. Also, as the request of the 
reviewers we have included some new data in the MS, which contains now 7 figures so 
as to accommodate these new data. 
The manuscript contains seven figures plus a supplementary Table and a supplementary 
figure.
* Cover Letter
1Dear Editor
We thank you very much for the review of our manuscript (MS) entitled 
“HCT116 cells deficient in p21WAF1 are hypersensitive to tyrosine kinase inhibitors 
and adriamycin through a mechanism unrelated to p21 and dependent on p53” by 
Ferrandiz et al.
The comments of the reviewers have certainly improved the MS. After 
performing a series of new experiments we believe that we have appropriately 
responded to all the points raised by the two reviewers. To illustrate of our responds we 
include in our response letter four “Figures for Reviewers”. Also, as the request of the 
reviewers we have included some new data in the MS, which contains now 7 figures so 
as to accommodate these new data. 
The point-by-point response to the reviewer’s comments follow.
Reviewer #1
1.HCT116 p21-/- cells seem to have higher levels of phosphorylated c-Abl and 
c-Src than parental HCT116 cells (Fig. 2). Could this contribute to the greater 
sensitivity of HCT116 p21-/- cells to TKIs?
The western blot of Fig 2 has been repeated with cell lysates from three independent 
experiments, with the same results, i.e., an increased level of Phospho-c-Abl and 
Phospho-c-Src in HCT116 p21-/- cells. The possibility that higher levels of phospho-c-
Abl contribute to the greater sensitivity to the drug is not consistent with the fact that 
HCT116 p21-/- are hypersensitive to a c-Abl inhibitor as imatinib. To test the point 
raised by the reviewer about c-Src, we have treated the cells with the c-Src inhibitor 
SU6656. We found that c-Src inhibition (assessed by p-c-Src levels) did not result in 
increased sensitivity of HCT116 cells and did not increase the sensitivity of imatinib 
(Fig. 1 for reviewers).
2. To conclude that the role of p21 on apoptosis of HCT116 cells should be re-
evaluated, the authors need to perform more studies with genotoxic agents. 
They have examined the response to adriamycin and 5-FU, but in many cases 
the analysis is not complete. For example, in Fig. 3h, the panel for HCT116 
p21-/- cells treated with 5-FU is missing. Fig. 1 shows the response of cells to 5-
FU only in panel A, etc.
We have performed a series of experiments with gefitinib and 5-FU. In the Version 2 of 
the MS we present these data in the new figures 1b, 3h and 7a. The results fully 
confirm those already shown for adriamycin and imatinib, i.e., a higher sensitivity of 
HCT116 p21-/- cells towards these drugs.
3. The experiment showing that restoring expression of p21 does not rescue the 
sensitivity ot imatinib needs to be improved, because only a small fraction of the 
cells express p21 after addition of Zn (Fig. 3b). Alternatively, the authors could 
use adenoviral infection (see comment 6, below).
All Hp21KO-MTp21 cells show p21 induction after ZnSO4 addition, as assessed by 
immunofluorescence and comparing with controls without Zn2+. However, some cells 
are particularly bright, and in the image presented in the first version of the MS the 
settings of brightnees/contrast gave the false idea that there are cells not expressing 
p21. In the Figure 3b of the MS-version 2, which we present again the image with a 
brighter setting so as all cells in the filed can be observed. We also show several more 
fields from an independent experiment in the Figure 2 for Reviewers. Importantly, we 
have used in all these images the same bright/contrast settings for the uninduced cells 
(i.e., without Zn2+) and for the induced cells. Although essentially all Hp21KO-MTp21 
* Response to Reviewers Comments
2cells overexpress p21 in response to the inducer, we do not know why there are cells 
expressing more p21 than others. It also happens with other cell types as leukemia 
cells with Zn-inducible p21 (Muñoz et al., J Biol. Chem., 2005) and p27 (Acosta et al., 
Mol. Cell Biol. In press). We hypothesize that there is a cell-cycle dependent transient 
stabilization of these CKIs.
4. The experiment showing p21 levels in HCT116 cells depleted of p21 after 
adriamycin treatment is very interesting (Fig. 3g). Apparently, adriamycin 
induces a significant increase in p21 levels, such that now in the adriamycin-
treated p21-depleted cells the levels of p21 are similar to the untreated non-
p21-depleted cells (lanes 6 versus 1). Thus, there is plenty of p21 in the p21-
depleted cells and this creates a problem in interpretation. Can the authors 
show the levels of p21 in the imatinib-treated cells? Can they achieve better 
suppression of p21 expression?
The experiments of Fig 3g were performed only to demonstrate the reduced p21 levels 
in the HCT-shp21B cell line. The results show that the expression of p21 was efficiently 
down-regulated in the absence of drugs. As we know that adriamycin is a potent p21 
inducer we also checked p21 levels in the presence of the drug (right lanes of the 
figure). The results show that despite this induction, the levels of p21 in adriamycin-
treated HCT-shp21B cells is two-fold less (as assessed by film densitometries in Fig. 
3g) than in adriamycin-treated control HCT116 control cells. Despite of that, we could 
not detect any significant differences between both cell lines in the sensitivity to the 
four drugs tested: adriamycin, imatinib, gefitinib and 5-fuorouracil. Moreover we have 
addressed the point raised by the reviewer and determined the p21 levels in both cell 
lines upon imatinib treatment. The results (shown the Fig 3g bottom panel of the MS-
Version 2) show that, conversely to adriamycin, imatinib does not induce p21. The 
figure again shows the reduced p21 levels in HCT-shp21B cells.
5. The high level of p53 activity in the HCT116 p21-/- cells (Fig. 4) could be due 
to the oncogenic signal provided by the high levels of phosphorylated c-Abl and 
c-Src in these cells. This could also explain why imatinib suppresses p53 
activation (Fig. 4b).
As indicated in the response to point #1, high c-Abl activity cannot be the reason fr the 
hypersentivity to imatinib. We also addressed the reviewer’s point by testing the effect 
of the c-Src inhibitor SU6656 on p53 levels. We found that upon c-Src inhibition 
(assessed by Phospho-Src immunoblot) augments the p53 levels in parental cells (not 
shown), but does not modify the p53 levels HCT116p21-/- cells (Fig. 1 for Reviewers). 
Furthermore, we think that unambiguously demonstrate that p53 overexpression is 
responsible for the high-sensitivity phenotype of HCT116p21-/- cells. First we show that
p53 reduction or inactivation rescues the low-proliferation phenotype of HCT116p21-/-
cells. We have repeated these experiments and now are presented in the Fig. 6c of the 
MS-Version 2 with error bars. Moreover, we present new data showing that silencing or 
inactivation of p53 efficiently antagonizes this hypersensitivity towards all tested drugs
(Fig 7 of MS-Version 2). Finally we also present new data showing that p53 down-
regulation (Hp21KO-shp53) or inactivation (Hp21KO-DDp53) results in a decrease in 
phosphorylated c-Abl and c-Src activity (new Fig. 7e of MS-Version 2). These results 
demonstrate that the hyperactivation of these kinases depend on the high p53 levels in 
the HCT116p21-/- cells.
6. Did the authors examine the sensitivity of adeno-p21-infected cells (Fig. 5c) 
to imatinib, 5-FU, etc?
We have performed the experiments suggested by the reviewer. The adenovirus 
infection was demonstrated by immunoblot of lysates prepared 24 h after the infection 
3(Figure 3a for Reviewers). 24 h after imatinib treatment we did not observe any 
protective effect of p21 (Fig. 3b for referees) At longer infection times (36-48 h) the p21 
virus induced cell death (new Fig 5d of MS-version2). 
Reviewer #2: 
1. The title wording, "..hypersensitive to tyrosine kinase inhibitors.through a 
mechanism unrelated to p21 and dependent on p53," implies that a p53-
dependent mechanism of HCT116p21-/- cell sensitivity to multiple tyrosine 
kinase inhibitors was demonstrated. Given the data in the manuscript, the 
authors can make this claim for imatinib but not gefitinib. While the gefitinib 
sensitivity of HCT116p21-/- cells is not due to p21 deficiency (Fig. 3h), the p53-
dependence of this sensitivity was not shown for gefitinib. The authors should 
show (or at least cite as "data not shown" if this experiment was done) an 
increase in gefitinib resistance in Hp21KO-shp53 and Hp21KO-DDp53 as was 
done for imatinib and adriamycin (Fig. 6f).
The reviewer is right in this criticism. We have performed new experiments comparing 
the sensitivity of HCT116p21-/-, Hp21KO-shp53, Hp21KO-DDp53 and parental HCT116 
towards adriamycin, gefitinb, imatinib and 5-FU (previously only shown for adriamycin 
and imatinib). The data shows that silencing of p53 with the siRNA-producing construct 
or inactivation with the dominant negative construct completely abolishes the 
hypersensitive phenotype as measured by cell proliferation/viability curves. This is 
presented in the Fig 7 of the MS-version 2. Moreover, p53 inactivation rescues the slow 
growing phenotype of HCTp21KO cells (Fig 7) These data, together with the data 
already presented in the Fig. 6 of the first version of the MS, reinforces our hypothesis  
2. The word "that" should be "than" in the sentence (1st paragraph of results, 
pg.6) ".these cells were more resistant to the kinase inhibitors that the p21-
deficient ."
The sentence has been changed.
3. A period is needed after the last sentence on pg. 6.
The period has been inserted
4. Consider changing the sentence (1st sentence, pg 7) ".as well as its partial 
dependence on p53, in a similar way than genotoxic drugs as adriamycin or 5-
FU." A suggested version is, ".as well as its partial dependence on p53, in a 
similar way as the genotoxic drugs adriamycin and 5-FU."
The reviewer is right and the sentence has been changed.
5. Hp21KO-MTp21 cells without zinc addition show a decrease in G1 population 
compared to HCT116p21-/- cells. Also, the decrease in the G1 population with 
zinc addition is modest. This needs to be discussed.
HCT21KO and HCTp21KO-MTp21 (without zinc) grow slower that parental cells with 
extended cell cycles, thus showing a higher G2 fraction. The experiments of Fig 3d 
were performed to show that p21 induction with zinc produced the described G1 to G2 
shift. We now give references to support this p21 effect (Refs 35 and 36 in the MS-
Version 2)
6. The correct name for p21 is Cdkna1 or CDKNA1 for the human gene, so I 
would change the sentence on p.2 to "Cdkna1/p21Waf1/p21Cip1" (p21 herein 
after) is a member.
The reviewer is right and the sentence has been changed.
47. The authors state that "Finally, we could not detect differences in p53 
proteinlevels (as assayed by immunoblot) in ascendant colon from p21-deficient 
mice and parental mice (not shown). In summary, the results indicate that 
HCT116p21-/- cells express higher p53 levels and exert higher p53 activity than 
parental cells, and that this was independent from its p21 deficiency." The 
authors are to be commended for doing these controls but this raises the issue 
of the generality of the effect: e.g. is it specific to tumor cells or perhaps only 
Hct116? Considering how frequently this line is used, it's worth reporting their 
observations.
We show the data in the Fig. 4 for Reviewers. The mice are from Jackson Labortories 
(B6;129S2-Cdkn1atm1Tyj/J) and described in Brugarolas et al., Nature 377(6549):552-7, 
1995. All this information were lacking and now we provide it the Methods section of 
the MS-Version 2
8. The p21-/- phenotype was reversed by inhibition of p53 as shown in Fig. 6. 
Regarding elevation of of phospho-Src, phospho-Abl, and others in Fig. 2, were 
these reversed by inhibition of p53? This would provide some mechanistic info 
for their observation
First, we show in the new version of the MS that p53 reduction or inactivation rescues 
the low-proliferation phenotype of HCT116p21-/- cells (Fig. 6c), and that silencing or 
inactivation of p53 efficiently antagonizes this hypersensitivity towards all tested drugs 
(Fig 7 of MS-Version 2). Finally we also present new data showing that p53 down-
regulation (Hp21KO-shp53) or inactivation (Hp21KO-DDp53) results in a decrease in 
phosphorylated c-Abl and c-Src activity. The data are now shown in the Fig. 7e of MS-
Version 2. This result demonstrates that the hyperactivation of these kinases depend 
on the high p53 levels in the HCT116p21-/- cells.
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Fig. 1. c-Src inhibition does not modify the sensitivity of imatinib. (a) 
HCT116p21-/- cells were treated with the c-Src inhibitor SU6656 for 24h 
and/or imatinib for 20h and p-c-Src, c-Src, p21, p53 and actin were 
analysed by immunoblot. As a control, a lysate from HCT116 cells 
treated with 0.5 µM adriamycin for 48 h (HCT+Adr) was included. 
(b) Micrographs of HCT116p21-/- cells treated with SU6656 for 48h 
and 20 μM imatinib showing similar sensitivity of imatinib in the 
presence and absence of the c-Src inhibitor. 
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Figure 2 for referees Ferrandiz et al.
Fig. 2. Induction and nuclear localization of p21 in 
Hp21KO-MTp21 cells. Immunofluorescence analysis with 
anti-p21 antibody was performed in cells untreated 
(Control) or treated for 12 h with 50 μM ZnSO4 (Zn2+ ).
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Fig. 3. HCT116p21-/- cells infected with p21 adenovirus were 
sensitive to imatinib. (a) Cells were infected with adenovirus carrying 
p21 gene and GFP and 24 h after infection whole-cell protein 
extracts were analysed by immunoblot with antibodies against p21 
and actin. As a control, a lysate from HCT116 cells treated with 0.5 
µM adriamycin was included. (b) Apoptosis induction after treatment 
with imatinib for 24 h. Fraction of cells in sub G0/G1 phase and 
annexin V binding were determined by flow cytometry.
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Fig. 4. Colon samples from parental mice and p21-
deficient mice do not show differences in p53 
protein levels. Whole-cell lysates from ascendant
colon tissues were analysed by immunoblot with 
antibodies against p21, p53 and Actin. A 
representative blot is shown.
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